DNER and medulloblastoma: Brain tumors, including GBM, DIPG, and subsets of medulloblastoma, bear dismal prognoses with current therapies, and while BET protein inhibitors have been positively tested in preclinical trials with these pathologies, clinical trials currently are in early stages. Future directions include more extensive preclinical trials of brain tumors with various BET protein inhibitors as they continue to be developed, as well as translation of promising results to phase I/II clinical trials.